Compare CF Industries Holdings, Inc. (CF) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CF Industries Holdings, Inc. vs Twist Bioscience Corp — how do they compare? CF Industries Holdings, Inc. trades at $117.69 (market cap $18.38B), while Twist Bioscience Corp trades at $122.96 (market cap $7.82B). The key difference: CF Industries Holdings, Inc. is far larger — about 2.4× Twist Bioscience Corp's market cap, and CF Industries Holdings, Inc. pays a 1.98% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CF | TWST | |
|---|---|---|
Market Cap | $18.38B | $7.82B |
Sector | Basic Materials | Health |
52-Week High | $137.55 | $124.88 |
52-Week Low | $76.08 | $24.16 |
Enterprise Value | $19.52B | $7.75B |
Dividend Yield | 1.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CF Industries Holdings (CF) trades at $114.35, down 2.04% today, reflecting a bearish technical trend with support at $112 and resistance at $116. The company reported mixed Q2 2026 earnings, missing EPS estimates at $4.73 versus $5.63 expected, but revenue grew 17.6% year-over-year on strong nitrogen pricing. Fundamentals remain solid with a P/E of 8.48 and net income margin of 27.12%, while cash flow improved to $368 million in 2025. Recent news highlights institutional buying and nitrogen market tightness supporting mid-cycle earnings.
Outlook is cautiously optimistic; CF benefits from robust nitrogen demand and pricing, with analyst consensus target at $119.60 implying upside. Risks include volume volatility from plant outages and debt levels, but high ROE (39.19%) and dividend payments signal financial health. Investors may find value at current levels if operational execution aligns with favorable industry conditions.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
